InvestorsHub Logo
Followers 5
Posts 1919
Boards Moderated 1
Alias Born 07/04/2017

Re: Edward post# 72103

Tuesday, 07/25/2017 8:11:19 PM

Tuesday, July 25, 2017 8:11:19 PM

Post# of 144823
Go over your DD again.

"It is important for our shareholders to realize that PharmaCyte’s pancreatic cancer therapy is classified by drug regulatory authorities as a ‘biologic’ rather than a single molecule drug or a New Chemical Entity (NCE). This is because our therapy involves the use of living, genetically altered human cells. The overall development process is much more involved and more complex for a biologic than an NCE. Nevertheless, PharmaCyte’s therapy is moving forward at a realistic pace."
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PMCB News